Arcus Biosciences, Inc.RCUS财报
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
RCUS Q4 2025 Key Financial Metrics
营收
$11.0M
毛利润
N/A
营业利润
$-114.0M
净利润
$-106.0M
毛利率
N/A
营业利润率
-1036.4%
净利率
-963.6%
同比增长
-52.2%
EPS
$-0.88
资金流向
Arcus Biosciences, Inc. Q4 2025 财务摘要
Arcus Biosciences, Inc. reported revenue of $11.0M (down 52.2% YoY) for Q4 2025, with a net profit of $-106.0M (down 12.8% YoY) (-963.6% margin). Cost of goods sold was N/A.
核心财务指标
| 总营收 | $11.0M |
|---|---|
| 净利润 | $-106.0M |
| 毛利率 | N/A |
| 营业利润率 | -1036.4% |
| 报告期 | Q4 2025 |
营收拆解
Arcus Biosciences, Inc. Q4 2025 revenue of $11.0M breaks down across 3 segments, led by Other at $5.0M (45.5% of total).
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Other | $5.0M | 45.5% |
| Other Collaboration Revenue | $4.0M | 36.4% |
| Access Rights And Option Continuation Periods | $2.0M | 18.2% |
Arcus Biosciences, Inc. 分部营收 — 季度趋势
Arcus Biosciences, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Other Collaboration Revenue) has evolved quarter over quarter.
| 业务分部 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Other | $5.0M | — | — | — |
| Other Collaboration Revenue | $4.0M | $6.0M | $8.0M | $8.0M |
| Access Rights And Option Continuation Periods | $2.0M | — | — | — |
Arcus Biosciences, Inc. 年度营收
Arcus Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $33.0M). Click any linked year to see what changed vs the prior 10-K.
Arcus Biosciences, Inc. 季度营收与净利润历史
Arcus Biosciences, Inc. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| Q4 2025 | $11.0M | -52.2% | $-106.0M | -963.6% |
| Q3 2025 | $6.0M | -14.3% | $-135.0M | -2250.0% |
| Q2 2025 | $8.0M | -27.3% | $0 | N/A |
| Q1 2025 | $8.0M | -20.0% | $-112.0M | -1400.0% |
| Q4 2024 | $23.0M | +146.9% | $-94.0M | -408.7% |
| Q3 2024 | $7.0M | -78.1% | $-92.0M | -1314.3% |
| Q2 2024 | $11.0M | -62.1% | $-93.0M | -845.5% |
| Q1 2024 | $10.0M | -60.0% | $-4.0M | -40.0% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $10.0M | $11.0M | $7.0M | $23.0M | $8.0M | $8.0M | $6.0M | $11.0M |
| 同比增长 | -60.0% | -62.1% | -78.1% | 146.9% | -20.0% | -27.3% | -14.3% | -52.2% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $1.29B | $1.19B | $1.25B | $1.15B | $1.16B | $1.07B | $974.0M | $1.14B |
| 总负债 | $586.0M | $551.0M | $687.0M | $665.0M | $625.0M | $526.0M | $538.0M | $508.0M |
| 股东权益 | $707.0M | $635.0M | $565.0M | $485.0M | $531.0M | $549.0M | $436.0M | $631.0M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $-2.0M | $-94.0M | $26.0M | $-100.0M | $-132.0M | $-133.0M | $-97.0M | $-120.0M |